1. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis 
Y. Huang, W.A. Border, D.A. Lawrence, N.A. Noble 
Kidney International 
Volume 70, Issue 3, Pages (August 2006)
DOI: /sj.ki
Copyright © 2006 International Society of Nephrology Terms and Conditions

2. Figure 1
Immunofluorescent staining for ECM produced in vitro by MCs. Original magnification × 400. Col IV, Collagen type IV; FN, fibronectin; LM, lamin; VN, vitronectin.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

3. Figure 2
Dose (a) and time (b) effects of wt-PAI-1 on ECM degradation. *P<0.01 vs control.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

4. Figure 3
Effect of PAI-1R alone on ECM degradation (a) and the protective effect of PAI-1R on wt-PAI-1-induced inhibition of ECM degradation (b–d). (c) *P<0.05 vs wt-PAI-1 alone treated. (d) *P<0.05 vs control, #P<0.05 vs wt-PAI-1 alone treated for 72 h.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

5. Figure 4
Plasmin activity in cultured supernatant after 72 h treatment was determined by a (a) chromogenic substrate assay and (b) 4–16% Zymogram. In the Zymogram assay, equal amount of culture supernatant was separated by 4–16% Zymogram (blue casein) gel. The gels were then incubated in the NOVEX zymogram renaturing buffer twice for 30 min at room temperature, and then incubated at 37°C overnight in NOVEX zymogram developing buffer. The gel was photographed by a Bio-Rad GS-700 imaging densitometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA). *P<0.05 vs Control, #P<0.05 vs wt-PAI-1 treated.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

6. Figure 5
Effects of plasmin inhibitors on the ability of PAI-1R to normalize the wt-PAI-1-induced inhibition of ECM degradation. *P<0.05 vs Control, #P<0.05 vs wt-PAI-1 alone treated. §P<0.05 vs PAI-1R and wt-PAI-1 treated.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

7. Figure 6
Effect of TA on 24-h urinary protein excretion from d5 to d6. *P<0.05 vs normal control (NC). #P<0.05 vs disease control (DC).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

8. Figure 7
Glomerular histology. Representative photomicrographs of glomeruli from normal control rats treated (d) with or (a) without TA, disease control rats treated (e) with or (b) without TA, and PAI-1R treated nephritic rats treated (f) with or (c) without TA at d6. (g) Graphic representation of PAS staining scores of each group. A total of 30 glomeruli per animal were scored for PAS staining, scores were averaged for each animal, and then for each group. *P<0.05 vs normal control (NC). #P<0.05 vs disease control (DC).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

9. Figure 8
Immunofluorescent staining score for ECM proteins at d6. FITC-conjugated rabbit anti-human fibrinogen/fibrin (DAKO, Carpinteria, CA, USA) was used directly. Monoclonal mouse anti-cellular fibronectin EDA+ (Harlan Sera-Lab Belton, England), goat anti-human type I collagen and goat anti-human type III collagen (Southern Biotechnology Associates, Birmingham, AL, USA) were used as primary antibodies with FITC-conjugated rat F (ab′)2 anti-mouse immunoglobulin G (H+l) (Jackson Immunoresearch laboratories, West Grove, PA, USA) and FITC-conjugated rabbit anti-goat immunoglobulin G (DAKO) as secondary antibodies. A total of 20 glomeruli per animal were scored for immunofluorescent staining, scores were averaged for each animal, and then for each group. *P<0.05 vs normal control (NC). #P<0.05 vs disease control (DC).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

10. Figure 9
Effect of TA on glomerular production of FN and TGF-β1 at d6. *P<0.05 vs normal control (NC). #P<0.05 vs disease control (DC).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

11. Figure 10
Effect of TA on glomerular mRNA expression of TGF-β1, PAI-1, fibronectin, and collagen I harvested 6 days after induction of glomerulonephritis. Representative Northern blot is shown in (a) and relative glomerular mRNA expression was shown in (b). *P<0.05 vs normal control (NC). #P<0.05 vs disease control (DC).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions

12. Figure 11
Number of monocytes/macrophages infiltrating glomeruli in anti-thy-1 nephritis at d6. *P<0.05 vs normal control (NC). #P<0.05 vs disease control (DC).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2006 International Society of Nephrology Terms and Conditions